1261653-43-3

Basic information

• Product Name: Benzoic acid, 3-broMo-2-cyano-, Methyl ester
• Synonyms: Benzoic acid, 3-broMo-2-cyano-, Methyl ester;methyl 3-bromo-2-cyanobenzoate;JTKBWUQNFHIFIW-UHFFFAOYSA-N
• CAS NO: 1261653-43-3
• Molecular Formula: C9H6BrNO2
• Molecular Weight: 240.05344
• EINECS: -0
• Mol File: 1261653-43-3.mol

Chemical Properties

• Boiling Point: 356.0±32.0 °C(Predicted)
• Appearance: /
• Density: 1.60±0.1 g/cm3(Predicted)
• CAS DataBase Reference: Benzoic acid, 3-broMo-2-cyano-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-broMo-2-cyano-, Methyl ester(1261653-43-3)
• EPA Substance Registry System: Benzoic acid, 3-broMo-2-cyano-, Methyl ester(1261653-43-3)

Safety Data

• Hazardous Substances Data: 1261653-43-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 3-bromo-2-cyano-, Methyl ester is used as a building block in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be incorporated into the development of new drugs, enhancing their therapeutic properties and effectiveness.
Used in Agrochemical Industry:
In the agrochemical industry, Benzoic acid, 3-bromo-2-cyano-, Methyl ester serves as a key intermediate in the production of various agrochemicals. Its versatile chemical properties enable it to be used in the formulation of pesticides, herbicides, and other agricultural chemicals, contributing to improved crop protection and yield.
Used in Dye and Pigment Manufacturing:
Benzoic acid, 3-bromo-2-cyano-, Methyl ester is also used as an intermediate in the manufacturing of dyes and pigments. Its chemical composition allows for the creation of a wide range of colors and shades, making it a valuable component in the production of various dyes and pigments used in different industries, such as textiles, plastics, and printing inks.

Upstream product

• 121772-84-7 methyl 2-iodo-3-bromobenzoic acid 
• 104670-74-8 methyl 2-amino-3-bromobenzoate 
• 20776-51-6 2-amino-3-bromo benzoic acid 

Relevant articles and documents

EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Biphenyl compound as well as preparation method and medical application thereof

The invention discloses a biphenyl compound as well as a preparation method and medical application thereof, the structure of the biphenyl compound is shown as a formula (I) or a formula (II), and thebiphenyl compound or pharmaceutically acceptable salt, tautomer, meso-isomer, raceme, stereoisomer, metabolite, metabolite precursor, prodrug or solvate thereof is a PD-L1 inhibitor. The compound hasa remarkable inhibiting effect on the interaction of PD-1 and PD-L1 protein, so that the compound can be applied to the preparation of PD-L1 inhibitors and immunomodulator drugs for preventing or treating tumors, autoimmune diseases, organ transplant rejection, infectious diseases and inflammatory diseases.

Benzoxadiazole compound and preparation method and medical use thereof

The invention discloses a benzoxadiazole compound and a preparation method and medical use thereof. The benzoxadiazole compound has the general structure shown in formula (I). The compound or pharmaceutically acceptable salts, tautomers, mesomers, racemates, stereoisomers, metabolites, metabolic precursors, prodrugs or solvates of the benzoxadiazole compound have an obvious inhibiting effect on PD-1/PD-L1 protein-protein interaction, so that the benzoxadiazole compound shown in the description can be applied to the preparation of an inhibitor with a PD-1/ PD-L1 inhibitory activity and the immunotherapy of tumors as an immunocheckpoint inhibitor.